Ryan Maves to Hospitalization
This is a "connection" page, showing publications Ryan Maves has written about Hospitalization.
Connection Strength
0.453
-
Spiro J, Wisniewski P, Schwartz J, Smith AG, Burger S, Tilley DH, Maves RC. Doxycycline Prophylaxis for Skin and Soft Tissue Infections in Naval Special Warfare Trainees, United States1. Emerg Infect Dis. 2024 Jan; 30(1):89-95.
Score: 0.193
-
Emuren L, Welles S, Polansky M, Evans AA, Macalino G, Agan BK. Lower health-related quality of life predicts all-cause hospitalization among HIV-infected individuals. Health Qual Life Outcomes. 2018 May 30; 16(1):107.
Score: 0.131
-
Epsi NJ, Powers JH, Lindholm DA, Mende K, Malloy A, Ganesan A, Huprikar N, Lalani T, Smith A, Mody RM, Jones MU, Bazan SE, Colombo RE, Colombo CJ, Ewers EC, Larson DT, Berjohn CM, Maldonado CJ, Blair PW, Chenoweth J, Saunders DL, Livezey J, Maves RC, Sanchez Edwards M, Rozman JS, Simons MP, Tribble DR, Agan BK, Burgess TH, Pollett SD. A machine learning approach identifies distinct early-symptom cluster phenotypes which correlate with hospitalization, failure to return to activities, and prolonged COVID-19 symptoms. PLoS One. 2023; 18(2):e0281272.
Score: 0.045
-
Blair PW, Brandsma J, Chenoweth J, Richard SA, Epsi NJ, Mehta R, Striegel D, Clemens EG, Alharthi S, Lindholm DA, Maves RC, Larson DT, Mende K, Colombo RE, Ganesan A, Lalani T, Colombo CJ, Malloy AA, Snow AL, Schully KL, Lanteri C, Simons MP, Dumler JS, Tribble D, Burgess T, Pollett S, Agan BK, Clark DV. Distinct blood inflammatory biomarker clusters stratify host phenotypes during the middle phase of COVID-19. Sci Rep. 2022 Dec 28; 12(1):22471.
Score: 0.045
-
Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, Marconi VC, Ruiz-Palacios GM, Hsieh L, Kline S, Tapson V, Iovine NM, Jain MK, Sweeney DA, El Sahly HM, Branche AR, Regalado Pineda J, Lye DC, Sandkovsky U, Luetkemeyer AF, Cohen SH, Finberg RW, Jackson PEH, Taiwo B, Paules CI, Arguinchona H, Erdmann N, Ahuja N, Frank M, Oh MD, Kim ES, Tan SY, Mularski RA, Nielsen H, Ponce PO, Taylor BS, Larson L, Rouphael NG, Saklawi Y, Cantos VD, Ko ER, Engemann JJ, Amin AN, Watanabe M, Billings J, Elie MC, Davey RT, Burgess TH, Ferreira J, Green M, Makowski M, Cardoso A, de Bono S, Bonnett T, Proschan M, Deye GA, Dempsey W, Nayak SU, Dodd LE, Beigel JH. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med. 2021 03 04; 384(9):795-807.
Score: 0.039